Zogenix (NASDAQ:ZGNX) announced its quarterly earnings data on Thursday. The company reported ($1.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.88) by ($0.20), Fidelity Earnings reports. During the same quarter in the previous year, the business posted ($1.68) EPS.
Zogenix stock traded down $2.55 during mid-day trading on Friday, reaching $40.75. The company had a trading volume of 1,013,089 shares, compared to its average volume of 625,195. Zogenix has a 1 year low of $32.40 and a 1 year high of $62.75. The stock has a market cap of $1.51 billion, a PE ratio of -10.14 and a beta of 1.86.
In other Zogenix news, EVP Gail M. Farfel sold 6,961 shares of the stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $43.23, for a total value of $300,924.03. Following the completion of the transaction, the executive vice president now directly owns 14,104 shares of the company’s stock, valued at $609,715.92. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gail M. Farfel sold 7,000 shares of the stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $47.58, for a total transaction of $333,060.00. The disclosure for this sale can be found here. Company insiders own 5.00% of the company’s stock.
A number of equities research analysts recently commented on the stock. Piper Jaffray Companies assumed coverage on shares of Zogenix in a research report on Monday. They issued an “overweight” rating for the company. Zacks Investment Research upgraded shares of Zogenix from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Thursday, October 25th. Leerink Swann restated an “outperform” rating on shares of Zogenix in a research report on Friday, October 19th. BidaskClub upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research report on Tuesday, October 16th. Finally, ValuEngine downgraded shares of Zogenix from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Zogenix has an average rating of “Buy” and an average target price of $71.90.
TRADEMARK VIOLATION WARNING: “Zogenix (ZGNX) Issues Earnings Results, Misses Expectations By $0.20 EPS” was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.wkrb13.com/2018/11/09/zogenix-zgnx-issues-earnings-results-misses-expectations-by-0-20-eps.html.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Featured Story: How much money do you need to begin day trading?
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.